Article

Multi-Analyte Liquid Biopsies for Molecular Pathway Guided Personalized Treatment Selection in Advanced Refractory Cancers: A Clinical Utility Pilot Study

2021-12-29

Abstract excerpt

<h4>Purpose</h4> The selection of safe and efficacious anticancer regimens for treatment of broadly refractory patients with metastatic cancers remains a clinical challenge. Such patients are often fatigued by toxicities of prior failed treatments and may have no further viable standard of care treatment options. Liquid Biopsy-based multi-analyte profiling in peripheral blood can identify a majority of drug target...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2eed622b-a5f0-5236-b63a-7099132f06ce
DOI: 10.1101/2021.12.23.21268152

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Multi-Analyte Liquid Biopsies for Molecular Pathway Guided Personalized Treatment Selection in Advanced Refractory Cancers: A Clinical Utility Pilot StudyDOI 10.1101/2021.12.23.21268152Read

Multi-Analyte Liquid Biopsies for Treatment Guidance in Advanced Refractory Cancers: Findings of the LIQUID IMPACT TrialSemantic proximity Read

Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice.Semantic proximity Read

The significance of using liquid biopsy to improve treatment outcomes for metastatic patientsSemantic proximity Read

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersSemantic proximity Read

Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapiesSemantic proximity Read

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read

Assessing In House Comprehensive Genomic Profiling by Liquid Biopsy for NSCLC PatientsSemantic proximity Read

AI enabled exome and transcriptome liquid biopsy platform spanning the continuum of care in oncologySemantic proximity Read

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read

Widespread adoption of precision anticancer therapies after implementation of pathologist-directed comprehensive genomic profiling across a large US health systemSemantic proximity Read

Incorporating tumor genomic profiling and drug screening through circulating tumor cell- derived organoids into clinical practice for the management of Gastrointestinal CancersSemantic proximity Read

Dissecting Tumor Heterogeneity by Liquid Biopsy—A Comparative Analysis of Post-Mortem Tissue and Pre-Mortem Liquid Biopsies in Solid NeoplasiasSemantic proximity Read